Adult Chronic Primary Immune Thrombocytopenia: Safety and Efficacyof Thrombopoietin Receptor Agonists and Rituximab

Authors

  • Zeina Al Achkar Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA Author
  • Nusrat Jahan Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA Author
  • Cesar Peralta Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA Author
  • Humera Batool Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA Author

DOI:

https://doi.org/10.47363/JDMRS/2021(2)123

Keywords:

Immune , Thrombopoietin, Rituximab, Thrombocytopenia

Abstract

Primary immune thrombocytopenia (ITP), one of the most common acquired autoimmune bleeding disorders characterized by immune-mediated destruction and defective platelet production, which increases the risk of bleeding.

Author Biographies

  • Zeina Al Achkar, Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

    Zeina Al Achkar, Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

  • Nusrat Jahan, Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

    Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

  • Cesar Peralta, Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

    Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA 

  • Humera Batool, Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

    Internal Medicine, California Institute of Behavioral Neuroscience and Psychology, Fairfield, USA

Downloads

Published

2021-04-24

Issue

Vol. 2 No. 2 (2021): Voulume 2 Issue 2

Section

Articles